CURIS INC
CRISDrugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
4
Next Catalyst
Mar 19, 2026
6dMarket Overview
Stock performance and key metrics
4 upcoming, 0 past
Earnings - emavusertib
Curis announced it will report fourth quarter 2025 financial and operating results on March 19, 2026, with a conference call and webcast. The company is developing emavusertib (CA-4948), an orally available IRAK4 and FLT3 inhibitor.
3 more catalysts beyond 14 days
Start a 48h free trial to see all upcoming catalysts
CUDC-907
Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations
Emavusertib
Acute Myelogenous Leukemia
Ibrutinib
Relapsed Hematologic Malignancy
Zanubrutinib
Chronic Lymphocytic Leukemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CUDC-907 | Phase 2 | Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations | - | - |
Emavusertib | Phase 2 | Acute Myelogenous Leukemia | - | - |
Ibrutinib | Phase 2 | Relapsed Hematologic Malignancy | - | - |
Zanubrutinib | Phase 2 | Chronic Lymphocytic Leukemia | - | - |